Radioligand therapy (RLT) may be new to some, but at Perceptive Imaging, nuclear medicine is in our DNA.
In a field where precision is everything, the cost of inexperience is high. Missteps in isotope selection, imaging protocols, or dosimetry strategy can derail timelines, compromise data integrity, and put patient safety at risk. That’s why 80% of sponsors trust Perceptive: we bring the scientific rigor, operational depth, and regulatory foresight needed to de-risk your RLT program — end to end.
We support the full lifecycle of theranostics and radioligand therapy trials — ensuring patient safety from early-phase dose optimization and biodistribution through global Phase III execution. With the right infrastructure, scientific expertise, and advanced imaging technology, we deliver high-quality data that accelerates development timelines and drives regulatory success to help you bring life-saving treatments to patients in need.
Perceptive is the industry’s most experienced imaging partner in radioligand / radiopharmaceutical therapy (RPT), supporting over 80 clinical trials and thousands of preclinical programs across a wide range of targets and tumor types.
We understand the operational complexity of radioligand therapy trials — and we’ve built the systems, teams, and partnerships to manage them at scale.
Whether you’re launching a first-in-human Ph 0 study or scaling a global Phase III, Perceptive offers a full suite of clinical imaging services tailored to radiopharmaceutical trials.
Site readiness is one of the most critical success factors in radioligand therapy trials. Perceptive has built the industry’s most robust site qualification and training infrastructure:
2,000+ PET/SPECT imaging centers qualified globally
Decades of experience in complex site setup, bringing new isotopes online
>99% of scans deemed evaluable across studies
Rigorous phantom-based qualification, dose calibration and harmonization workflows
Experience in working with variety of phantoms, including NEMA, Uniformity and Jaszczak.
Experienced logistics team ships Perceptive-owned phantoms to sites
Flexible training, teleconferences, web-based training and on-demand support.
Real-time QC of first-subject scans and continuous feedback loops.
Perceptive Imaging offers deep expertise in molecular imaging across different types of cancer, with a proven track record in PSMA-PET trials and a growing portfolio of support for emerging radioligand targets. Our team has helped shape the imaging standards for PSMA-based therapies and continues to lead innovation in tracer development, segmentation analytics, and trial design.
We are actively supporting clinical trials in a wide range of novel targets, including FAP, DLL3, HER2, GRPR, MC1R, STEAP1, TROPE2, PTK7, CAIX, and more. Whether you’re working with established tracers or pioneering new theranostic pairs, our imaging infrastructure and scientific leadership will give you confidence in the accuracy, reproducibility, and regulatory-readiness of your data, as you move forward in bringing new treatments, and hope, to the patients who need it the most.
Radiopharmaceutical therapies represent hope for many cancer patients and their loved ones, so the studies that support them require an understanding beyond just standard imaging. Since these therapies offer so much hope, and patient safety is at stake, it is absolutely critical you choose an imaging partner with deep understanding of tracer kinetics, organ-specific uptake, and radiation dose safety.
With the patient at the forefront of everything we do, our dedicated dosimetry and analytics teams bring unmatched expertise to every study:
60+ dosimetry studies supported across isotopes and indications
40-person advanced analytics and 10-person dosimetry teams
Organ- and tumor-specific dose estimates using validated models (e.g., OLINDA) and custom in-house tools
Support for multi-center, pediatric, and translational studies
Expertise across isotopes including At-211, Tb-161, Ac-225, Lu-177, Pb-212, Cu-64/67, Zr-89, and more
Perceptive is the only imaging core lab to date to support a radioligand therapy FDA submission using AI-derived quantitative PET data. Our proprietary PSMA segmentation platform, updated in April 2025, delivers:
This tool was developed and validated in the context of the VISION trial, and continues to evolve with new capabilities for emerging tracers and disease states.
Perceptive Imaging offers centralized PSMA tracer management and distribution services to simplify logistics and reduce site burden in radioligand therapy trials. Our team provides end-to-end oversight of tracer supply across global clinical sites, ensuring timely delivery, consistent communication, and seamless integration with imaging workflows.
